# A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

> **NCT01564537** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 722 (actual)

## Conditions studied

- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01564537
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-01
- **Primary completion:** 2014-10-01
- **Final completion:** 2022-02-08
- **Target enrollment:** 722 (ACTUAL)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564537, "A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01564537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*